ERBB2 and cancer: Importantly, studies carried out with a new class of anti-cancer agents (i.e., Disulfide bond Disrupting Agents [DDAs]), which target epidermal growth factor receptor (EGFR) and its family members HER2 and HER3 [13], show that DDAs disrupt CDCP1 ternary signaling complexes.